Immunovaccine appoints John Trizzino as CEO

Immunovaccine, Inc., a vaccine development company, announced the appointment of John J. Trizzino as chief executive officer effective October 1.
Trizzino will also be appointed to the board of directors of the corporation.

As a senior executive with over 25 years of broad industry experience, Trizzino has been instrumental in creating licensing agreements as well as sales to major pharmaceutical companies and government agencies, and in creating joint ventures.
"As our development program accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution," Albert Scardino, the chairman of Immunovaccine, said.
Trizzino joins Immunovaccine from Novavax, Inc., a clinical-stage vaccine company in Rockville, Md., where he served as senior vice president. He has also held senior executive positions at MedImmune, Inc., and ID BioMedical, Inc.
"The next phase of our development includes expanding the commercial potential of our early stage research partnerships," Scardino said. "That is John's specialty. He knows the public markets, private financing and government contracting, and with his broad experience in the biotechnology industry, we anticipate a high level of visibility for our pioneering delivery platform and our vaccines."
Trizzino is a graduate of Long Island University in New York City. He received his master's degree in business administration from New York University's Stern School of Business.
"Immunovaccine's technology has the potential to offer significant advances in the world of vaccines," Trizzino said. "To lead the company, as its human trials accelerate, is both an opportunity and a challenge. With strong business fundamentals, a broad intellectual property portfolio and a talented and committed scientific team, Immunovaccine has the building blocks in place. My goal is to focus on the therapeutic areas with the strongest growth potential and to expand the company's relationships within the global pharmaceutical and biotechnology industry."